바이오비쥬

489460KOSDAQ

59.3 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioViju is a global export-focused company specializing in the research, development, and manufacturing of hyaluronic acid (HA)-based skin boosters and fillers, utilizing cross-linking and LNP technologies to ensure product safety. With its own production facility and ISO certification, the company is expanding OEM and general distribution, aiming to secure growth momentum through the expansion of HA filler approvals both domestically and internationally.

Number of Employees

51people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

36.11Industry Average 15.000.0Point

2.4x industry avg (risky)

PBR

2.56Industry Average 1.200.0Point

2.1x industry avg (risky)

ROE

8.94Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

0.31Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 85

Positive
"글로벌 에스테틱 기업으로 발돋움"…바이오비쥬 6%↑[특징주]
바이오비쥬의 주가가 증권가 긍정 전망에 힘입어 장 초반 상승하며 강세를 보임.
Positive
"바이오비쥬, 美 진출 본격화…글로벌 에스테틱 기업 발돋움"
바이오비쥬의 북미 시장 진출 확대와 신사업 확장으로 글로벌 에스테틱 시장에서의 성장 잠재력이 높게 평가됨.
Positive
바이오비쥬, 다음달10일 '셀리비온' 그랜드 론칭 세리머니 개최
바이오비쥬의 셀리비온 ECM 스킨리바이저 론칭 행사 발표로 인해 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 10,760Won52-week high 16,97052-week low 5,530

1-month return3.0Point

1m 0.09% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-12